查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2023年至2028年血友病市场预测
市场调查报告书
商品编码
1410056

2023年至2028年血友病市场预测

Hemophilia Market - Forecasts from 2023 to 2028
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 143 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

血友病市场预计将从2021年的111.27亿美元成长到2028年的168.19亿美元，复合年增长率为6.08%。

血友病是一种罕见疾病，凝血因子缺乏会导致血液凝固异常。结果就是流鼻血、疼痛、水肿、关节紧绷和神秘出血。全球人口中血友病的盛行率不断上升及其对个人的相关不利影响预计将推动血友病市场的发展。此外，血友病药物的产品上市、政府的频繁核准以及优惠政策预计将进一步推动血友病市场的发展。

血友病患病率增加

世界各地血友病病例数量的不断增加表明了治疗的需要，并对血友病市场做出了积极贡献。例如，根据世界血友病联合会2021年报告，2021年共有233,577例血友病确诊病例，其中A型血友病病例185,318例。根据世界血友病联盟的数据，自 2020 年以来，盛行率增加了 9%，1999 年至 2021 年间增加了 296%。由于血友病在全球发病率较高，血友病治疗药物的使用将会增加，从而刺激血友病市场的扩大。

血友病的多种副作用

血友病引起的多种併发症显示需要能够推动血友病市场的治疗方法。内出血会损害组织和器官，甚至可能致命。对于一些患有严重血友病的人来说，即使头部受到轻微的打击也会导致大脑出血，这是一个严重的问题。此外，内出血也会因关节压力而引起疼痛不适。如果不定期治疗内出血，可能会导致关节恶化和关节炎。此外，一些患有严重血友病的人对用于治疗出血的凝血剂有严重的免疫系统反应。在这些情况下，免疫系统会产生阻止凝血因子作用的蛋白质，进而降低药物的疗效。

有利的政府政策

多项努力和政策正在推动血友病市场的发展，包括政府核准血友病治疗方法。例如，BioMarin Pharmaceutical 开发的A型血友病基因治疗药物 Roctavian 于 2023 年 6 月获得 FDA核准。 2023 年 2 月，欧盟委员会核准了uniQure 开发的首个针对成人B型血友病的基因疗法。此外，为了改善出血性疾病患者获得临床试验的机会，美国血友病联合会于 2023 年 6 月宣布了新的工具和搜寻功能。

该领域研究计划的增加

血友病持续需要增加先进治疗的研究计划和临床试验，以推动血友病市场的发展。 2023 年 5 月，辉瑞宣布 Marstacimab 在关键的 3 期A型血友病 A和 B 试验中取得了积极结果。该试验显示，与预防性治疗和按需静脉注射治疗相比，年出血率显着降低。此外，2023年3月，美国国家血友病基金会宣布推出治癒之路（P2C），这是一项新的350万美元风险慈善投资基金，旨在改变包括血友病在内的所有遗传性血液疾病。）计划启动。

市场抑制因素

除了所有促进成长的因素外，预计还会出现限制血友病市场成长的因素。血友病市场预计将因高昂的治疗成本和普遍缺乏对新兴技术的认识而受到阻碍。基因疗法可能提供一种治疗血友病的新方法，但价格昂贵，每剂花费 350 万美元。此外，血友病的基因治疗并不总是有效。此外，特定血友病的病因不明是血友病市场的另一个抑制因素，使治疗方法开发和测试变得复杂。

北美地区预计将大幅成长

预计在预测期内，北美地区将占据血友病市场的很大一部分。促成因素包括血友病病例增加、意识提升和技术进步。例如，每 5,000 名男性中就有 1 人患有A型血友病，在美国，每年有 400 名婴儿出生时患有A型血友病。根据世界血友病联合会2021的调查显示，2020年美国有14,816名血友病患者，其中包括A型血友病（11,790例）和B型血友病（30,026例）在内。此外，为了帮助那些无助的血友病患者应对自己的问题，还设立了“全国血友病宣传月”，这也带动了该地区的血友病市场。

血友病市场参与者

CSL Behring 是领先的生物製药公司之一，专注于血浆衍生和重组治疗产品。公司产品包括人类凝血因子VIII製剂Biostate（R）、人类凝血因子XII製剂Cluviate（R）、凝血因子XIII製剂Cluvot（R）、凝血因子XIII浓缩物Corifact（R） .我们提供的一些血液製品。诺和诺德成立于 1923 年，总部位于丹麦，是开发严重慢性疾病治疗方法的领先医疗保健公司之一。该公司正在探索血友病和罕见血液疾病的创新长效皮下治疗解决方案，并于 2020 年 2 月推出了A型血友病治疗药物 ESPEROCT®。罗氏 (Roche) 是一家总部位于瑞士的医疗保健公司，成立于 1896 年。该公司开发的治疗A型血友病的Hemlibra(R)于2018年获得美国FDA核准。

新兴市场的主要发展

2022 年 5 月，Precision Biologics 经当地卫生当局核准后，在加拿大、欧盟、澳洲和纽西兰推出了 CRYOcheck 显色因子 IX 检测方法。它是为了测量B型血友病患者的 FIX 活性而开发的。 2022年11月，UniQure宣布2023年推出首款B型血友病基因疗法Hemgenix，斥资350万美元。它已获得美国政府核准，计划于 2023 年发布。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第二章调查方法

  • 调查资料
  • 先决条件

第三章执行摘要

  • 研究亮点

第四章市场动态

  • 市场驱动因素
  • 市场抑制因素
  • 波特五力分析
  • 产业价值链分析

第五章血友病市场：依疾病类型

  • 介绍
  • A型血友病
  • B型血友病
  • 其他的

第六章 血友病市场：治疗方法

  • 介绍
  • 替代疗法
  • 基因治疗
  • 其他（免疫耐受性诱导治疗等）

第七章 血友病市场：依产品类型

  • 介绍
  • 重组凝血因子浓缩物
  • 血浆衍生凝血因子浓缩物
  • 其他（去氨加压素等）

第八章 血友病市场：依地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作

第十章 公司简介

  • Bayer AG
  • BioMarin Pharmaceutical, Inc.
  • CSL Behring
  • Novo Nordisk
  • Pfizer, Inc.
  • Roche（Chugai Pharmaceutical Co.）
  • Sanofi（Genzyme Corporation）
  • Takeda Pharmaceutical（Shire Plc.）
  • Grifols
简介目录
Product Code: KSI061615707

The hemophilia market is expected to grow at a CAGR of 6.08% from US$11.127 billion in 2021 to US$16.819 billion in 2028.

Hemophilia is a rare disorder in which there are insufficient clotting factors, resulting in improper blood clotting. This results in nosebleeds, pain, edoema, tightness in the joints, and inexplicable bleeding. The growing prevalence of hemophilia among the world population along with its associated adverse effects on individuals is contemplated to boost the hemophilia market. Moreover, the product launches and frequent government approvals for the hemophilia drug along with the favourable policies are further expected to propel the hemophilia market.

Growing Prevalence of Hemophilia Disease

The rising cases of hemophilia worldwide indicate the need for treatment and thus contribute positively to the hemophilia market. For instance, there were 233,577 identified patients with hemophilia in 2021 including 185,318 cases of hemophilia A as per the World Federation of Hemophilia Report 2021. The prevalence rate has increased by 9% from 2020 and 296% between 1999 and 2021 according to the World Federation of Hemophilia. With such a high frequency of hemophilia worldwide, medicines for the condition will be used more frequently, fueling the expansion of the hemophilia market.

Multiple Associated Adverse Effects of Hemophilia

The multiple complications caused by hemophilia indicate the requirement of treatment therapies thereby propelling the hemophilia market. Internal bleeding can injure tissues and organs and is potentially fatal. Some persons with severe hemophilia can experience bleeding into the brain after a minor hit on the head which is a major serious problem. Moreover, internal bleeding may cause agonizing discomfort due to joint pressure. If untreated, internal bleeding regularly can cause joint deterioration or arthritis. Additionally, the immune system reacts badly to the clotting medications used to treat bleeding in some people with severe hemophilia. When this happens, the immune system creates proteins that block the action of the clotting factors, decreasing the efficacy of the medication.

Government Favorable Policies

Several efforts and policies such as approvals by the government in the hemophilia treatment therapies are advancing the hemophilia market. For instance, a gene therapy Roctavian developed by BioMarin Pharmaceutical for hemophilia A was granted approval by the FDA in June 2023. The European Commission approved the first gene therapy in February 2023 for adults with hemophilia B developed by uniQure. Additionally, to improve access to clinical trials for those with bleeding disorders, the Haemophilia Federation of America unveiled a new tool and search function in June 2023.

Rising Research Projects in the Field

The hemophilia disorder is continuously looking for a rise in research projects and clinical trials for advanced treatment thereby propelling the hemophilia market. In May 2023, Pfizer announced the positive Marstacimab results from pivotal phase 3 hemophilia A and B trials. This study showed a significant reduction in annualized bleeding rate compared to prophylaxis and on-demand intravenous regimes. Moreover, in March 2023, the National Haemophilia Foundation will launch Pathway to Cures (P2C), a new $3.5 million venture philanthropy investment fund that aims to have a transformative effect on all inheritable blood illnesses, including hemophilia.

Restraints in the Market

Apart from all the growth drivers, some factors are expected to limit the hemophilia market growth. The hemophilia market is anticipated to be hampered by the high cost of therapy and the general lack of awareness of emerging technology. While gene treatments might offer a novel approach to treating hemophilia, they can be expensive, costing up to $3.5 million for a single dose. Additionally, gene treatments for hemophilia aren't always effective. Moreover, the unknown causes of certain hemophilia represent another restraint in the hemophilia market making it complex to develop and experiment with the therapies.

North America is Expected to Grow Significantly

During the forecast period, the North American region is anticipated to account for a sizeable portion of the hemophilia market. Various factors attributed to such a share are rising hemophilia cases, increasing awareness, and technological advancements. For instance, 1 in 5,000 male babies has hemophilia A. Each year, 400 infants are born with hemophilia A in the US. According to the World Federation of Haemophilia 2021 study, there were 14,816 hemophilia patients in the United States in 2020, including those with hemophilia A (11,790 cases) and hemophilia B (30026 cases). Moreover, National Haemophilia Awareness Month was established to raise awareness of the condition and discover solutions to assist hemophiliacs who might feel helpless to deal with their issues during March each year which also boosts the hemophilia market in the region.

Hemophilia Market Players

  • CSL Behring is one of the leading biopharmaceutical companies focused on plasma-derived and recombination therapeutic products. Biostate® for human coagulation factor VIII, Cluviate® for human coagulation factor XII, Cluvot® for factor XIII, and Corifact® for factor XIII Concentrate are some of the hematology products offered by the company.
  • Novo Nordisk, founded in 1923 and headquartered in Denmark is one of the leading healthcare companies to develop treatments for serious chronic diseases. The company is exploring innovative long-acting and subcutaneous treatment solutions for hemophilia and rare blood disorders and it launched ESPEROCT® for hemophilia A treatment in February 2020.
  • Roche is a Switzerland-based healthcare company serving the people since 1896. Hemlibra® developed by the company for the treatment of hemophilia A was granted approval by the US FDA in 2018.

Key Market Developments

  • In May 2022, Precision Biologic launched the CRYOcheck Chromogenic Factor IX assay in Canada, the EU, Australia, and New Zealand after approval of health authorities in the respective countries. It was developed for the determination of FIX activity in patients with hemophilia B.
  • In November 2022, UniQure announced the launch of the first hemophilia B gene therapy Hemgenix by 2023 with a price tag of $3.5 million. It is approved by the US government and is expected to launch by 2023.

Segmentation:

By Disease Type

  • Hemophilia A
  • Hemophilia B
  • Others

By Therapy

  • Replacement Therapy
  • Gene Therapy
  • Others (Immune Tolerance Induction Therapy etc.)

By Product Type

  • Recombinant Coagulation Factor Concentrates
  • Plasma-derived Coagulation Factor Concentrates
  • Others (Desmopressin etc.)

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. HEMOPHILIA MARKET BY DISEASE TYPE

  • 5.1. Introduction
  • 5.2. Hemophilia A
  • 5.3. Hemophilia B
  • 5.4. Others

6. HEMOPHILIA MARKET BY THERAPY

  • 6.1. Introduction
  • 6.2. Replacement Therapy
  • 6.3. Gene Therapy
  • 6.4. Others (Immune Tolerance Induction Therapy etc.)

7. HEMOPHILIA MARKET BY PRODUCT TYPE

  • 7.1. Introduction
  • 7.2. Recombinant Coagulation Factor Concentrates
  • 7.3. Plasma-derived Coagulation Factor Concentrates
  • 7.4. Others (Desmopressin etc.)

8. HEMOPHILIA MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. The Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations

10. COMPANY PROFILES

  • 10.1. Bayer AG
  • 10.2. BioMarin Pharmaceutical, Inc.
  • 10.3. CSL Behring
  • 10.4. Novo Nordisk
  • 10.5. Pfizer, Inc.
  • 10.6. Roche (Chugai Pharmaceutical Co.)
  • 10.7. Sanofi (Genzyme Corporation)
  • 10.8. Takeda Pharmaceutical (Shire Plc.)
  • 10.9. Grifols